Appointment of CEO

Tristel PLC

17 June 2026

 

Tristel plc

("Tristel" or the "Company")

Appointment of CEO

Tristel plc (AIM: TSTL), the manufacturer of infection prevention products, announces the appointment of Christopher ("Chris") Lee as Chief Executive Officer ("CEO"), with effect from 1 August 2026. Chris's appointment follows the conclusion of a competitive selection process, and he will replace Matt Sassone, who is leaving on 30 June to take up a worldwide president role with a large US multinational. Anna Wasyl, Chief Financial Officer, will act as interim CEO ahead of Chris joining.

Chris joins the Company following a successful career in the medical technology sector, most recently serving as Chief Executive Officer of Summit Medical Ltd, a UK-based medical device group, from 2020 to 2025. During his tenure, Chris led the strategic development and growth of the business, overseeing its operations across multiple subsidiaries and driving expansion in international markets.

Prior to this, Chris was CEO of Venner Medical International, a Jersey-based developer and manufacturer of respiratory and anaesthesia products, from 2013 to 2020. He continues to serve as Non-Executive Chairman of Venner Medical Deutschland GmbH, a position he has held since October 2013. Earlier in his career, Chris held senior leadership roles at Teleflex Incorporated, a global medical technology company, where he was Vice President, Global Integration, and at LMA International, where he served as General Manager and Deputy Group CEO.

Chris has over 35 years' experience in the medical technology and healthcare industry, spanning senior management, commercial leadership and operational roles including an 18-year career at Johnson & Johnson. He began his career in sales and has extensive international experience across Europe and the United States.

Chris holds an MBA from Cranfield University and a Diploma in Marketing from Napier University, Edinburgh.

Chris Lee, new Chief Executive Officer of Tristel plc

Chris Lee, incoming CEO of Tristel, commented: "I am delighted to join the Tristel team as Chief Executive Officer, and to continue to build on the Company's leading position in infection prevention globally. I join at an exciting time in the development of the business and I appreciate the efforts made to ensure a smooth transition in leadership. I am pleased to be leading a business that remains well-positioned to deliver against its growth strategy and I look forward to working with a dedicated and passionate team who have built a solid foundation based on proprietary technology and an unwavering commitment to quality and service."

Bruno Holthof, Chair of Tristel, commented: "We are delighted to welcome Chris to Tristel and his industry experience, especially in the US, makes him the ideal person to lead the business as we drive further growth from what is a well-established platform. We remain confident in our future growth and look forward to Chris's input and insight as we continue to drive overseas expansion."

For further information please contact:     

Tristel plc			Via Walbrook PR
Matt Sassone, Chief Executive Officer			https://investors.tristel.com/
Anna Wasyl, Chief Financial Officer
Walbrook PR Ltd	Tel: [phone] or [e-mail]
Paul McManus / Lianne Applegarth / Anna Dunphy		Mob: [phone]
Cavendish Capital Markets Ltd			Tel: [phone]
Geoff Nash / Callum Davidson / Joe Smith (Corporate Finance)
Sunila de Silva (Corporate Broking) / Louise Talbot (Sales)

About Tristel plc

Tristel plc is a global infection prevention company focussed on the manufacture and supply of products using its unique proprietary chlorine dioxide (ClO2) chemistry. The Company is a market leader in manual decontamination of medical devices, supplying hospitals with products under the Tristel brand, which also encompasses its sporicidal surface disinfection range offered as a sustainable alternative to commonly used pre‑wetted plastic wipe.

Tristel's head office and manufacturing facility is located in Snailwell, near Cambridge, and operates globally employing approximately 270 people across 16 subsidiaries selling into 40+ countries. The Company targets delivering double-digit revenue growth annually, an adjusted EBITDA margin of at least 25% and a continuing progressive year-on-year growth in dividends, underpinned by robust cash generation. 

The Company has been listed on the London Stock Exchange's AIM market since 2005 (AIM: TSTL).

For more information about Tristel's product range please visit: https://tristel.com 

INFORMATION REQUIRED UNDER RULE 17 AND SCHEDULE 2, PARAGRAPH (G) OF THE AIM RULES FOR COMPANIES ("AIM RULES")

Full name:	Christopher Paul Lee
Age:	63
Shares held in the Company:	None
Options held in the Company:	None
Current directorships and partnerships:	Venner Medical Deutschland GmbH Harrogate Street BPRA LLP Baron House BPRA LLP
Historic directorships and partnerships in previous 5 years:	Summit Medical UK Limited Orthodesign Limited Summit Medical Limited Summit Medical Group Limited Marshall Contracts Limited Summit Medical (Benefits) Limited Bowmoor Topco Limited Marlux Medical Limited Orthod Midco Limited

There is no further information to be disclosed in relation to the appointment pursuant to Rule 17 and Schedule 2, paragraph (g) of the AIM Rules.

 

END